10-QPeriod: Q3 FY2002

VERTEX PHARMACEUTICALS INC / MA Quarterly Report for Q3 Ended Sep 30, 2002

Filed November 14, 2002For Securities:VRTX

Summary

Vertex Pharmaceuticals Inc. reported a net loss of $33.45 million for the third quarter of 2002, a significant increase from the $11.48 million loss reported in the same period of 2001. This widening loss is primarily driven by a substantial increase in research and development expenses, which grew by 31% year-over-year to $50.62 million. Total revenues also declined by 15% to $34.28 million in the third quarter of 2002 compared to the prior year, with decreases noted in product sales and service revenues within the Discovery Tools and Services segment. Despite the increased losses, the company highlights continued investment in its pharmaceutical pipeline, with over a dozen drug candidates in development for various diseases. Collaborations with major pharmaceutical companies like GlaxoSmithKline and Novartis provide ongoing financial support for these research programs. The company anticipates continued losses in the foreseeable future due to ongoing R&D investments and commercialization expenditures.

Key Highlights

  • 1Net loss for Q3 2002 was $33.45 million, a substantial increase from $11.48 million in Q3 2001.
  • 2Research and development expenses increased significantly by 31% to $50.62 million in Q3 2002, reflecting continued investment in drug development.
  • 3Total revenues decreased by 15% to $34.28 million in Q3 2002, primarily due to lower product sales and service revenues in the Discovery Tools and Services segment.
  • 4Pharmaceuticals segment royalties remained stable, while collaborative R&D revenue saw a modest increase, partly due to the Novartis collaboration.
  • 5The company continues to advance its pipeline with over a dozen drug candidates in pre-clinical and clinical development.
  • 6Vertex expects to continue incurring losses in the foreseeable future due to ongoing R&D and commercialization efforts.

Frequently Asked Questions

The primary reason for the increased net loss in the third quarter of 2002 was a significant rise in research and development expenses, which grew by 31% year-over-year to $50.62 million, alongside a decrease in total revenues.

Vertex's operations have been funded through strategic collaborations, alliances, product sales, royalties, and existing cash and marketable securities. As of September 30, 2002, the company held $651.35 million in cash and marketable securities, though this represented a decrease from the prior year-end.

The company expects increased milestone payments, product revenues, and royalty payments in the coming years as they commercialize more products. However, revenue from the Discovery Tools and Services segment is not expected to be replaced at the same level as current contracts expire.

Vertex is involved in two notable legal proceedings: one with Chiron Corporation regarding patent infringement related to hepatitis C research, and another with Oregon Health Sciences University concerning ownership of neurophilin patents. The company believes these claims are without merit and does not expect them to have a material impact on its financial position.